Nakagawa Ryusuke, Inui Takuo, Nagafune Ikuko, Tazunoki Yoshiko, Motoki Kazuhiro, Yamauchi Akira, Hirashima Mitsuomi, Habu Yoshiko, Nakashima Hiroyuki, Seki Shuhji
Department of Cell Regulation, Kagawa Medical University, Kagawa, Japan.
J Immunol. 2004 Jun 1;172(11):6550-7. doi: 10.4049/jimmunol.172.11.6550.
We recently reported that NK cells and CD8(+) T cells contribute to the antimetastatic effect in the liver induced by alpha-galactosylceramide (alpha-GalCer). In the present study, we further investigated how CD8(+) T cells contribute to the antimetastatic effect induced by alpha-GalCer. The injection of anti-CD8 Ab into mice 3 days before alpha-GalCer injection (2 days before intrasplenic injection of B16 tumors) did not inhibit IFN-gamma production nor did it reduce the NK activity of liver mononuclear cells after alpha-GalCer stimulation. However, it did cause a reduction in the proliferation of liver mononuclear cells and mouse survival time. Furthermore, although the depletion of NK and NKT cells (by anti-NK1.1 Ab) 2 days after alpha-GalCer injection no longer decreased the survival rate of B16 tumor-injected mice, the depletion of CD8(+) T cells did. CD122(+)CD8(+) T cells in the liver increased after alpha-GalCer injection, and antitumor cytotoxicity of CD8(+) T cells in the liver gradually increased until day 6. These CD8(+) T cells exhibited an antitumor cytotoxicity toward not only B16 cells, but also EL-4 cells, and their cytotoxicity significantly decreased by the depletion of CD122(+)CD8(+) T cells. The critical, but bystander role of CD122(+)CD8(+) T cells was further confirmed by adoptive transfer experiments into CD8(+) T cell-depleted mice. Furthermore, it took 14 days after the first intrasplenic B16/alpha-GalCer injection for the mice to generate CD8(+) T cells that can reject s.c. rechallenged B16 cells. These findings suggest that alpha-GalCer activates bystander antitumor CD122(+)CD8(+) T cells following NK cells and further induces an adaptive antitumor immunity due to tumor-specific memory CD8(+) CTLs.
我们最近报道,自然杀伤(NK)细胞和CD8(+) T细胞有助于α-半乳糖神经酰胺(α-GalCer)诱导的肝脏抗转移作用。在本研究中,我们进一步探究了CD8(+) T细胞如何促成α-GalCer诱导的抗转移效应。在注射α-GalCer前3天(脾内注射B16肿瘤前两天)给小鼠注射抗CD8抗体,既不抑制干扰素-γ的产生,也不降低α-GalCer刺激后肝脏单核细胞的NK活性。然而,它确实导致肝脏单核细胞增殖减少以及小鼠存活时间缩短。此外,尽管在注射α-GalCer两天后耗尽NK和NKT细胞(通过抗NK1.1抗体)不再降低注射B16肿瘤小鼠的存活率,但耗尽CD8(+) T细胞却会降低存活率。注射α-GalCer后,肝脏中CD122(+)CD8(+) T细胞增加,并且肝脏中CD8(+) T细胞的抗肿瘤细胞毒性在第6天前逐渐增强。这些CD8(+) T细胞不仅对B16细胞表现出抗肿瘤细胞毒性,对EL-4细胞也有此作用,并且通过耗尽CD122(+)CD8(+) T细胞,其细胞毒性显著降低。将其过继转移到CD8(+) T细胞耗尽的小鼠体内的实验进一步证实了CD122(+)CD8(+) T细胞的关键但旁观者作用。此外,在首次脾内注射B16/α-GalCer后14天,小鼠才产生能够排斥皮下再次接种的B16细胞的CD8(+) T细胞。这些发现表明,α-GalCer在NK细胞之后激活旁观者抗肿瘤CD122(+)CD8(+) T细胞,并进一步诱导因肿瘤特异性记忆CD8(+) 细胞毒性T淋巴细胞(CTL)产生的适应性抗肿瘤免疫。